Skip to Content
Merck
CN
  • Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

Drug metabolism and disposition: the biological fate of chemicals (2008-04-23)
R Scott Obach, Franco Lombardo, Nigel J Waters
ABSTRACT

We present herein a compilation and trend analysis of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data. This data set provides the drug metabolism scientist with a robust and accurate resource suitable for a number of applications, including in silico modeling, in vitro-in vivo scaling, and physiologically based pharmacokinetic approaches. Clearance, volume of distribution at steady state, mean residence time, and terminal phase half-life were obtained or derived from original references exclusively from studies utilizing i.v. administration. Plasma protein binding data were collected from other sources to supplement these pharmacokinetic data. These parameters were analyzed concurrently with a range of simple physicochemical descriptors, and resultant trends and patterns within the data are presented. Our findings with this much expanded data set were consistent with earlier described notions of trends between physicochemical properties and pharmacokinetic behavior. These observations and analyses, along with the large database of human pharmacokinetic data, should enable future efforts aimed toward developing quantitative structure-pharmacokinetic relationships and improving our understanding of the relationship between fundamental chemical characteristics and drug disposition.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ibuprofen
Sigma-Aldrich
Dichloroacetic acid, ReagentPlus®, ≥99%
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Sigma-Aldrich
Mevinolin from Aspergillus sp., ≥98% (HPLC)
Supelco
D(−)-Norgestrel, analytical standard
Sigma-Aldrich
6-Aminocaproic acid, BioUltra, ≥99%
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
6-Aminocaproic acid, ≥99% (titration), powder
Sigma-Aldrich
β-Estradiol, BioReagent, powder, suitable for cell culture
Sigma-Aldrich
Trimethoprim, ≥98.5%
Supelco
Methimazole, analytical standard
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Nitrofurantoin, 98.0-102.0% (EP, UV)
Supelco
Digoxin, analytical standard
Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Acetylsalicylic acid, ≥99.0%
Sigma-Aldrich
2-Propylpentanoic acid
Sigma-Aldrich
17α-Ethynylestradiol, ≥98%
Sigma-Aldrich
(−)-Cotinine, ≥98%
Supelco
(−)-Cotinine solution, drug standard, 1.0 mg/mL in methanol
Supelco
(−)-Nicotine solution, 1.0 mg/mL, analytical standard, for drug analysis
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Sigma-Aldrich
2-Fluoroadenine-9-β-D-arabinofuranoside, DNA synthesis and methylation inhibitor
Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder